Genrix (shanghai) Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Genrix (shanghai) Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test safety of experimental drug GR2303 Results expected Sep 2026 (estimated)
- New hope for Hard-to-Treat blood cancer: experimental drug shows promise Results expected May 2027 (estimated)
- New shot could tame hay fever misery Results expected May 2027 (estimated)
- New biologic GR1803 aims to tame lupus in early trial Results expected Jun 2027 (estimated)
- New antibody drug GR2301 begins safety tests in healthy people Results expected Jul 2027 (estimated)
-
New hope for Hard-to-Treat blood cancer: experimental drug shows promise
Disease control OngoingThis study tests an experimental drug called GR1803 in 116 people with multiple myeloma that has come back or stopped responding to treatment. The goal is to see how well the drug shrinks or controls the cancer, and to check its safety. Participants receive the drug for up to 2 y…
Phase 2 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New injection could help nasal polyp sufferers avoid surgery
Disease control OngoingThis Phase 3 trial tests an experimental drug called GR1802 for adults with severe chronic rhinosinusitis with nasal polyps. The goal is to see if the drug can shrink polyps, ease congestion, and reduce the need for surgery or steroids. 228 participants will receive either GR1802…
Phase 3 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC